-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28, the NMPA official website showed that the review status of Tanabe Mitsubishi's new imported drug Titagliptin was changed to under review, and it is expected to be approved in the near future
Teneligliptin (TENELIA®) is a DPP-4 inhibitor diabetes drug.
According to a multi-center, randomized, double-blind, placebo-controlled clinical study covering 2119 patients with type 2 diabetes, TENELIA® (ticagliptin) single-agent treatment compliance rate reached 70% and reduced HbA1c (glycated hemoglobin) 0.
At present, the incidence of type 2 diabetes in adults in China has reached 10.
As the targeted drugs for oral preparations (GLP-1, DPP-4, SGLT-2) have been gradually launched in China in the past two years and have been included in the national medical insurance, these targeted drugs have begun to increase in volume in China
In March 2020, Servier China has signed an agreement with Tanabe Mitsubishi Group to promote the drug in China
